This HTML5 document contains 183 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33416593
rdf:type
wikibase:Item
schema:description
научни чланак 2014年學術文章 vědecký článek bilimsel makale სამეცნიერო სტატია مقالة علمية نشرت بتاريخ 17-7-2014 videnskabelig artikel (udgivet 2014) 2014년 논문 مقالهٔ علمی 2014 թվականի հուլիսին հրատարակված գիտական հոդված научная статья artículu científicu espublizáu en 2014 article scientific 2014年の論文 ২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2014 nî lūn-bûn naučni članak 2014年学术文章 articolo scientifico мақолаи илмӣ мақолаи илмӣ scientific article 2014年學術文章 vedecký článok artikulong pang-agham articol științific mokslinis straipsnis 2014年学术文章 επιστημονικό άρθρο artigo científico (publicado na 2014) artykuł naukowy 2014年學術文章 artigo científico (publicado na 2014) bài báo khoa học teaduslik artikkel 2014年學術文章 научна статия artículo científico publicado en 2014 מאמר מדעי artigo científico 2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած научни чланак наукова стаття, опублікована в липні 2014 vitenskapelig artikkel wetenschappelijk artikel tieteellinen artikkeli artikull shkencor 2014年学术文章 บทความทางวิทยาศาสตร์ article científic 2014年学术文章 article scientifique (publié 2014) tudományos cikk vitskapeleg artikkel سائنسی مضمون 2014年學術文章 2014年学术文章 wissenschaftlicher Artikel scienca artikolo 2014年學術文章 vetenskaplig artikel
p:P577
wds:Q33416593-3659F2FF-E648-48D5-B364-76F3DCCE3D37
wdt:P577
2014-07-17T00:00:00Z
p:P407
wds:Q33416593-C53ED94F-05E6-4CD9-BF34-8EF60775E9BA
wdt:P407
wd:Q1860
p:P2860
wds:Q33416593-1366A6AB-E9D2-49D3-860C-3FF01BFB0BA6 wds:Q33416593-FC5DECA3-7754-48B3-A139-55C3F24F5120 wds:Q33416593-FA1F69CA-E956-4257-A3AE-9C5CA1B9D4FA wds:Q33416593-FA7C02B4-E24D-4027-87CC-497FA07602E0 wds:Q33416593-F46D4516-596A-4F58-A777-36C1D3695A69 wds:Q33416593-C6610570-88D2-4FC5-A27C-4E1CE8450882 wds:Q33416593-D77E9B27-28F4-4E99-ACB2-A36EC11B037A wds:Q33416593-E14E04AB-AED5-4881-9AA0-CBCEB02342EF wds:Q33416593-C2664027-9ACD-42B1-AEA0-92209CE1CF42 wds:Q33416593-B9906D26-033C-4AD9-9ADE-E65E9EE3C6E3 wds:Q33416593-BA83F706-C9C7-4836-A39A-F83F30F564B3 wds:Q33416593-ACFE2569-AD03-4504-8B85-C8F8FFCC1AA2 wds:Q33416593-945AC619-A977-4495-9922-54D893818CD8 wds:Q33416593-95FE2DF3-AFBF-45C6-853D-A14320499DA6 wds:Q33416593-A4AD82B6-D107-47E4-ADE1-22ABB9BFCD16 wds:Q33416593-75A6FF38-5526-4BDC-8A04-F3DB3D630EC4 wds:Q33416593-7EC71953-84E1-4BD2-A3C0-F60A6704A5CE wds:Q33416593-433CE82B-48FC-41FA-B679-C88E7F55881F wds:Q33416593-62A3FDA5-CFC7-47A6-89A2-4A2D6A8FDA54 wds:Q33416593-6648F74E-2081-4CE7-ADA0-C8FB59C2A4D3 wds:Q33416593-3D460628-3058-45D2-B5E1-152A8C49DE14 wds:Q33416593-2EACA494-3BE0-4D87-8BA1-EA94BC0EB83D wds:Q33416593-19C2B1D8-5ADB-4561-BED7-6EDB4375AF0E wds:Q33416593-1B0786A0-88D1-4F6E-B725-3C53B191749E
wdt:P2860
wd:Q28204313 wd:Q40318856 wd:Q24633214 wd:Q28251216 wd:Q34742742 wd:Q34621900 wd:Q33407265 wd:Q34245261 wd:Q34566901 wd:Q29620690 wd:Q34368710 wd:Q34523108 wd:Q35730160 wd:Q28248195 wd:Q84932161 wd:Q33893704 wd:Q40005246 wd:Q27861018 wd:Q34641279 wd:Q47582438 wd:Q34625316 wd:Q30371806 wd:Q46669969 wd:Q33412064
p:P2093
wds:Q33416593-0D3F0DF0-C7A1-4863-9F4F-DD6B8C8F37B3 wds:Q33416593-1657A438-C88C-4EBE-A0E1-7EFCA6E7E92C wds:Q33416593-11E5EF04-6D59-4B96-A59A-B8D7985DFCE2 wds:Q33416593-3CAEE77E-D13B-465F-8A0A-9F753840D12C wds:Q33416593-388274B3-5D50-4198-836D-2CB26EF12A06 wds:Q33416593-48958BCB-8F07-45AF-A83F-A5223BFDCED1 wds:Q33416593-3400A649-39D9-471F-84AC-11EC2DFEE248 wds:Q33416593-2B8550FA-702F-4257-A9A1-84A2B29CE0D8 wds:Q33416593-A7E51C69-A0C8-4A40-B9E7-88A39EAE9040 wds:Q33416593-75EAE3A6-6608-4E9A-BD66-87B176C540D7 wds:Q33416593-66F610F1-49CB-496C-901E-56143A61416F wds:Q33416593-EC930393-F6CD-4C7E-8683-A4698B38DFBC wds:Q33416593-BDC109E0-39C4-49A5-9727-E3DAA784BA6D
wdt:P2093
Anas Younes Sriram Balasubramanian Nele Fourneau Peter Hellemans Nibedita Bandyopadhyay Yasuhiro Oki Jonathan W Friedberg Sandy Amorim Jessica Vermeulen Benedicte Hivert Franck Morschhauser Johan W Smit Ronald de Vries
rdfs:label
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
skos:prefLabel
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
schema:name
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
p:P50
wds:Q33416593-EB7FDBA7-AF1B-4D26-814C-1025DBE25B3D wds:Q33416593-208CAB7D-E2B9-4E72-B05E-0BD5F5BA7591 wds:Q33416593-AE035253-4D0D-47C2-9A3D-FA161FEFB87E
wdt:P50
wd:Q41604017 wd:Q46831307 wd:Q87856104
p:P1476
wds:Q33416593-1ACAFE94-6142-4ECA-8656-14A059BCDFD1
wdt:P1476
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
p:P304
wds:Q33416593-A4D908EE-509C-4C23-9742-68DD7D3324B3
wdt:P304
1019-1026
p:P31
wds:Q33416593-0D043147-9CAA-4B93-BE69-E50A3EE52B7F
wdt:P31
wd:Q13442814
p:P921
wds:Q33416593-1560EAC4-4072-41C4-AEB3-2132677DB471 wds:Q33416593-1BCD0B1C-4580-4A0F-943C-BCC29A1CF49F wds:Q33416593-BF1AC341-87CE-4699-BC73-86DC8689C704 wds:Q33416593-EDD6E0D2-0A3F-4190-B0C5-0189DC5812D1 wds:Q33416593-FB150718-2402-4276-8ED3-32546BEC1151
wdt:P921
wd:Q5984881 wd:Q55785695 wd:Q1138590 wd:Q18936 wd:Q412323
p:P698
wds:Q33416593-B283DDD4-7E12-44BD-AEA6-ACB97B3AE189
wdtn:P698
n12:25042202
wdt:P698
25042202
p:P1433
wds:Q33416593-FAFB830F-7E67-4884-8BF4-7F40964BD3FB
wdt:P1433
wd:Q13747613
p:P433
wds:Q33416593-9634EC90-3EDF-4AF6-9E3A-16BA7C9B8BD5
p:P478
wds:Q33416593-A8CE0FF7-F584-4410-B7CF-E7BDC7BED6BB
wdt:P433
9
wdt:P478
15
p:P356
wds:Q33416593-DC690BED-4060-4EED-9326-50AA8279109B
wdtn:P356
n11:S1470-2045(14)70311-0
wdt:P356
10.1016/S1470-2045(14)70311-0